DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - General

Daiichi Sankyo Co., Ltd.

4568JPX¥2,818−¥19 (−0.67%)Market closed

Price Chart

Daily

Key facts

Market Cap
¥5.13T
P/E
20.1x
P/B
3.13x
ROE
15.8%

Daiichi Sankyo Co., Ltd.

Healthcare · Drug Manufacturers - General · FY 2026

Daiichi Sankyo Co., Ltd. is a prominent pharmaceutical company based in Japan, specializing in the research, development, and manufacturing of pharmaceutical products. The company's primary focus is on developing innovative treatments across several critical therapeutic areas such as oncology, cardiovascular diseases, and rare genetic conditions. Notable for its robust pipeline of drugs, Daiichi Sankyo aims to leverage cutting-edge science in antibody-drug conjugates and other novel drug delivery systems to provide advanced treatments for unmet medical needs. As a key player in the global pharmaceutical industry, Daiichi Sankyo impacts multiple sectors, including healthcare services and biotechnology. Its strategic collaborations with other leading global pharmaceutical companies further enhance its growth prospects and innovation capabilities. Headquartered in Tokyo, Japan, and with a broad international footprint, Daiichi Sankyo holds significant market significance. It plays a vital role in advancing global healthcare solutions, ensuring a pipeline of emerging therapies can address future challenges in medical treatment.

CEO
Mr. Hiroyuki Okuzawa
Employees
19,765

Company Statistics

Valuation

P/E
20.1x
P/B
3.13x
P/S
2.46x
EV/EBITDA
14.5x
P/FCF
−73.1x

Margins

Gross
68.5%
EBITDA
16.4%
Operating
10.8%
Pre-Tax
12.4%
Net
12.2%

Returns

ROA
7.0%
ROE
15.8%
ROIC
7.3%

Growth (CAGR)

Rev 3Yr
18.4%
Rev 5Yr
17.1%
Op Inc 3Yr
23.9%
Net Inc 3Yr
33.5%

Financial Health

Cash & Cash Equivalents
¥449.81B
Net Debt
¥1.89T
Debt/Equity
140.7%
Interest Cov
—

Profile

Revenue
¥2.12T
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Daiichi Sankyo Co., Ltd. (4568) Stock Forecast 2026 ¥2,818 — Price, Financials & Analyst Targets | AlphaLenz